Spectrum Settles With Glaxo Over Imitrex

Law360, New York (November 13, 2006, 12:00 AM EST) -- Specialty drug maker Spectrum Pharmaceuticals Inc. has settled a patent infringement suit with GlaxoSmithKline over the use of the migraine injection treatment Imitrex.

The deal, announced Monday, will allow Spectrum to exclusively distribute generic Imitrex in the United States starting no later than Nov. 6, 2008. Spectrum added that the expected launch date is August of that year, around the time Glaxo’s pediatric exclusivity period begins for sumatriptan, the active ingredient in Imitrex.

“This settlement with GlaxoSmithKline for sumatriptan injection represents another milestone,” said Spectrum’s President...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.